Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
- Conditions
- Brain Injuries, Traumatic
- Registration Number
- NCT04893837
- Lead Sponsor
- University of Alabama at Birmingham
- Brief Summary
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.
- Detailed Description
MOBI-1 is a single-arm, multi-center derivation / validation study that will evaluate the use of the Infrascanner for monitoring traumatic intracranial hematomas. All patients will receive standard care plus hourly infrascanner assessments. This study will test the hypotheses that:
1. The Infrascanner has sufficient diagnostic performance to detect the expansion of intracranial hematomas
2. Patients who have expanding intracranial hematomas will be identified faster when monitored with hourly infrascanner assessments compared to standard care alone
3. Clinical / research staff will be able to attain all data points and relay the assessments to the medical team.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 440
- Age 15 or older
- Admission CT Scan shows intracranial hemorrhage
- Glasgow Coma Scale less than 15
- Neurosurgery service determines initial care is nonoperative
- Admitted for observation for TBI, to either step-down unit or intensive care unit
- Inability to provide informed consent or lack of a legally authorized representative (LAR)
- Admitted and observed for >2 hours prior to screening (i.e., has already received second neurological check)
- Other injuries deemed non-survivable
- Diagnosed with hemorrhagic shock or receives a large volume transfusion (>3 units of any blood product within any 1 hour)
- Planned surgical interventions/ procedures during study period (before the second CT scan)
- Known prisoner
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic performance of the infrascanner Month 24 Number of participants whose Infrascan results were accurate
- Secondary Outcome Measures
Name Time Method Time to detection of an enlarging hematoma 0-12 hours Difference in time to detection of hematoma enlargement between Infrascan and second CT across the cohort
Trial Locations
- Locations (2)
UAB Hospital
🇺🇸Birmingham, Alabama, United States
University of Arizona
🇺🇸Tucson, Arizona, United States
UAB Hospital🇺🇸Birmingham, Alabama, United StatesJan O Jansen, MBBS, PhDContact205-975-2393jjansen@uabmc.eduShannon W StephensContact205-934-5890swstephens@uabmc.edu